Literature DB >> 28557618

Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.

Rima Ait-Belkacem1, Vanesa Bol2, Gregory Hamm1, Florence Schramme3, Benoit Van Den Eynde3, Lauranne Poncelet1, Fabien Pamelard1, Jonathan Stauber1, Bruno Gomes2.   

Abstract

Inhibition of NK and effector T-cell functions and activation of regulatory cell populations are the main immunosuppressive effects of indoleamine-2,3-dioxygenase1 (IDO1). By converting tryptophan (Trp) into kynurenine (Kyn), IDO1 is involved in the immune response homeostasis, and its dysregulated expression is described in immune-related pathologies, as tumors that hijack it to evade immune destruction. Thereby, IDO1 inhibitors are being developed to stimulate antitumor immune responses. Existing and standard quantitation methods of IDO1 substrate and metabolite(s) are based on the total level of Trp and its metabolites determined by liquid chromatography tandem mass spectrometry analysis in human plasma, cerebrospinal fluid, and brain. Here, we describe the detection, localization, and absolute quantitation of Trp and Kyn by quantitative mass spectrometry imaging (qMSI) in transfected murine tumor models expressing various levels of IDO1. Myeloid, glycolysis metabolic signatures, and correlation between IDO1 expression and Trp to Kyn conversion are also shown. High-definition IDO1 and GCN2 immunostainings overlaid with Kyn molecular images underline the tumor metabolism and heterogeneity. The development of immunotherapies such as IDO1 inhibitors requires a deep understanding of the immune system, the interplay of cancer cells, and biomarker characterization. Our data underline that qMSI allows the study of the spatial distribution and quantitation of endogenous immune metabolites for biology and pharmacology studies.

Entities:  

Keywords:  IDO1; biomarker; kynurenine; quantitative MSI; tryptophan

Mesh:

Substances:

Year:  2017        PMID: 28557618     DOI: 10.1177/2472555217712659

Source DB:  PubMed          Journal:  SLAS Discov        ISSN: 2472-5552            Impact factor:   3.341


  6 in total

1.  Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.

Authors:  Jorge Blando; Anu Sharma; Maria Gisela Higa; Hao Zhao; Luis Vence; Shalini S Yadav; Jiseong Kim; Alejandro M Sepulveda; Michael Sharp; Anirban Maitra; Jennifer Wargo; Michael Tetzlaff; Russell Broaddus; Matthew H G Katz; Gauri R Varadhachary; Michael Overman; Huamin Wang; Cassian Yee; Chantale Bernatchez; Christine Iacobuzio-Donahue; Sreyashi Basu; James P Allison; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-11       Impact factor: 12.779

2.  Quantitative Mass Spectrometry Imaging Reveals Mutation Status-independent Lack of Imatinib in Liver Metastases of Gastrointestinal Stromal Tumors.

Authors:  Denis Abu Sammour; Christian Marsching; Alexander Geisel; Katrin Erich; Sandra Schulz; Carina Ramallo Guevara; Jan-Hinrich Rabe; Alexander Marx; Peter Findeisen; Peter Hohenberger; Carsten Hopf
Journal:  Sci Rep       Date:  2019-07-23       Impact factor: 4.379

Review 3.  Kynurenine Pathway Metabolites as Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Vanessa X Tan; Gilles J Guillemin
Journal:  Front Neurosci       Date:  2019-09-20       Impact factor: 4.677

Review 4.  The therapeutic potential of targeting tryptophan catabolism in cancer.

Authors:  Luis F Somarribas Patterson; Soumya R Mohapatra; Dyah L Dewi; Christiane A Opitz; Ahmed Sadik; Michael Platten; Saskia Trump
Journal:  Br J Cancer       Date:  2019-12-10       Impact factor: 7.640

5.  Non-Invasive, Topical Sampling of Potential, Low-Molecular Weight, Skin Cancer Biomarkers: A Study on Healthy Volunteers.

Authors:  Skaidre Jankovskaja; Maxim Morin; Anna Gustafsson; Chris D Anderson; Boglarka Lehoczki; Johan Engblom; Sebastian Björklund; Melinda Rezeli; György Marko-Varga; Tautgirdas Ruzgas
Journal:  Anal Chem       Date:  2022-04-08       Impact factor: 8.008

6.  Lipidomic analysis of immune activation in equine leptospirosis and Leptospira-vaccinated horses.

Authors:  Paul L Wood; Margaret Steinman; Erdal Erol; Craig Carter; Undine Christmann; Ashutosh Verma
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.